Vents MagaZine Music and Entertainment Magazine
Related Articles
Exceptional Sensitivity; Identifying Cancers Markers
Cancer known for its nature leaves behind molecular traces that can be challenging to detect within the intricate landscape of human proteins. However, enzyme linked immunosorbent assays (ELISAs) possess a sensitivity that allows them to pick up on these signals – measuring cancer biomarkers at extremely low concentrations often before any visible symptoms appear.
The remarkable sensitivity is attributed to their ability to specifically capture target molecules using antibodies along with processes that enhance the signals. This precision has enabled ELISA tests to identify biomarkers like prostate antigen (PSA) at low levels facilitating early detection of prostate cancer.[1] Similarly the use of ELISA to measure cancer antigen 125 (CA 125) has proven valuable in tracking cancer progression.[2]
By recognizing these molecular indicators ELISA assays provide healthcare professionals with an opportunity to intervene at the earliest stages when cancer is most manageable and patient outcomes are significantly improved.[3] This exceptional sensitivity positions ELISA procedure as a tool in the battle against cancer, by shining a light on the disease before it can establish a grip.
Multiplexed Cancer Profiling
Understanding cancer, in its complexity requires a knowledge of the web of biomolecules involved. Multiplexed ELISAs have become a tool for measuring panels of cancer biomarkers offering a comprehensive view of the disease status.[4]
Advancements in technology such as planar microarrays and suspension bead arrays have allowed for the creation of ELISA platforms. These systems utilize capture antibodies with encoding or colour coded microparticles to establish assay regions for each biomarker within a single well or flow cytometry channel.[5] This parallel approach enables the assessment of biomarkers, from just one patient sample streamlining the analysis process.
The practice of multiplexed cancer biomarker profiling comes with benefits, including enhanced disease classification and staging pinpointing targets and monitoring treatment responses.[6] By combining data from biomarkers, ELISAs can unveil the molecular patterns that contribute to cancer heterogeneity opening doors to more personalized and efficient interventions.[7]
Precision Medicine Unleashed
The emergence of precision medicine, which focuses on tailoring treatments, for patients based on their characteristics has revolutionized the approach to treating cancer. ELISA tests play a role in supporting this shift by measuring biomarkers to help choose targeted therapies.[8]
For instance, evaluating the levels of human epidermal growth factor receptor 2 (HER2) through ELISA examinations is vital in identifying breast cancer patients who may benefit from HER2 targeted treatments like trastuzumab.[9] Likewise detecting KRAS mutations using ELISA tests aids in classifying cancer patients for EGFR monoclonal antibody therapy.[10]
By uncovering the characteristics of each patient’s condition ELISAs equip oncologists with the insights to align personalized therapies, with individual needs. This personalized approach improves treatment efficacy and minimizes side effects ultimately resulting in outcomes and quality of life.[11]
Enhancing Cancer Screening and Monitoring
It is crucial to remain vigilant and proactive in managing cancer. ELISAs have become tools, for cancer screening programs and post treatment surveillance due to their ability to handle large volumes efficiently and their adaptability for automation.[12]
The integration of automated ELISA platforms with liquid handling systems allows for processing of numerous patient samples simultaneously targeting various cancer biomarkers.[13] This streamlined process enables cost screening initiatives on a scale increasing the likelihood of detecting cancer in its early stages when treatment is most successful.
Furthermore, the quantitative nature of ELISAs enables tracking of biomarker levels over time enabling healthcare providers to monitor disease progression or recurrence following treatment.[14] This continuous monitoring facilitates interventions, leading to patient outcomes and reducing healthcare expenses linked to managing advanced stage diseases.
Through the optimization of cancer screening and surveillance procedures ELISAs have emerged as tools in combating this illness offering optimism for a future where cancer detection and management are more efficient, than ever before.
References:
1. Stephan C, et al. (2006) Lancet Oncol. 7(7):556-569
2. Moss EL, et al. (2005) Gynecol Oncol. 99(1):197-207
3. Etzioni R, et al. (2003) Nat Rev Cancer 3(4):243-252
4. Tighe PJ, et al. (2015) Nat Rev Drug Discov. 14(3):173-189
5. Krishhan VV, et al. (2009) Curr Opin Mol Ther. 11(5):577-593
6. Shi Q, et al. (2017) Theranostics 7(7):1598-1622
7. Olsen D, et al. (2014) Adv Drug Deliv Rev. 81:28-38
8. Jackson SE, et al. (2015) Br J Cancer 112(4):628-632
9. Wolff AC, et al. (2007) J Clin Oncol. 25(2):118-145
10. Ardito CM, et al. (2012) J Cell Physiol. 227(10):3333-3344
- Jain KK (2015) Curr Opin Mol Ther. 17(3):274-285
- Robertson JL, et al. (2017) J Immunol Methods 439:19-28
- Jebrail MJ, et al. (2015) J Vis Exp. (100):e52976
- Duffy MJ (2001) Ann Clin Biochem. 38(Pt 6):629-633
